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Synopsis
Contrast-enhanced CT examination can influence H-MRI measurements performed within 24h after the CT scan, due to a reduction in water T  and T  caused
by the iodinated contrast agents used in CT. We have investigated whether contrast from a previous CT examination would also influence metabolic
measurements made using P-MRS, by measuring the T  of H and P signals in human blood. We find that iodinated CT contrast agent has no effect on
phosphorus T s. Therefore, P-MRS examinations will not be influenced by prior CT (unlike H-MRI scans).
Introduction:
Cardiac MRI is a routine non-invasive imaging modality used to diagnose heart disease. It can quantify cardiac anatomy, function, perfusion and cardiac tissue energy
metabolism. The latter is mainly probed by in vivo phosphorus MR spectroscopy ( P-MRS), which allows measurement of high-energy metabolites, e.g. adenosine
triphosphate (ATP) and phosphocreatine (PCr). The PCr/ATP concentration ratio has been shown to change in most major cardiac disease states . However, owing in part
to long scan times and comparatively limited spatial resolution, it is common to combine MRI with other imaging modalities for a more complete characterisation of cardiac
disease. In particular, contrast-enhanced computed tomography (CT) is frequently used. As it is beneficial to schedule the CT and MR examinations in close succession, it is
important to identify any potential interference between the two examinations. CT contrast agents contain iodine and act to shorten the T  and T  relaxation times of water
signals in proton ( H) MRI for up to 24 hours after the CT scan . However, any potential confounding effects on P-MRS remain unknown.
Therefore, our aim was to determine whether an iodinated contrast agent affects the longitudinal (T ) relaxation time of P metabolites, and thus whether an earlier contrast
enhanced CT scan would potentially influence the quantification of the cardiac PCr/ATP ratio.
Materials and Methods:
All measurements were performed using a vertical bore 11.7T MRI system (Bruker Avance) equipped with a dual-tuned H/ P RF 20mm diameter birdcage coil (Rapid
Biomedical).
Fresh human blood (4 × 4mL vials) was obtained from healthy volunteers via antecubital fossa venepuncture and stored in EDTA buffer (Vacutainer, BD Healthcare). T
relaxation times were measured on both channels ( H and P) in one vial sequentially after sampling using a non-localized pulse-acquire progressive saturation sequence
with 6 TRs (1s, 3s, 6s, 10s, 15s and 30s), hard pulse excitation (150ms duration, θ≈60° nominal flip angle), 32 averages, sw=30kHz. The T  measurement was performed
before and repeated after the addition of a clinically indicated dose of iodinated contrast agent, Iopamidol (1.5mL/kg, i.e. 80mL/vial), and the whole experiment was finished
within 2 hours after blood sampling. Water signal from the H spectra and 2,3-diphosphoglycerate (2,3-DPG) signal from the P spectra were fitted as Lorentzians using a
Matlab (Mathworks) implementation of AMARES , and used for determining mono-exponential T  relaxation curves in Matlab. The two peaks of 2,3-DPG were summed
together for the mono-exponential fitting of T s.
The remaining three vials were then used to acquire high SNR, partially saturated P spectra (TR=1s, θ≈60°, 512 averages) before and after the addition of Iopamidol. The
same fitting routine was used to fit the signals of 2,3-DPG, phosphodiesters (PDE), γ-ATP and α-ATP. A paired unequal variance t-test was used to compare the fitted signals
with and without contrast agent, with p<0.05 considered statistically significant.
Results and Discussion:
Figure 1 depicts the T  fits of water and 2,3-DPG signals from H and P MRS acquisitions of blood, respectively. The water T  shortened after adding Iopamidol from
4.8±1.9s to 2.2±0.1s. This is in good agreement with previous observations of reduced proton T  in MRI after using iodinated contrast agents . On the other hand, the T  of
DPG remained unchanged after mixing with the contrast agent, 3.7±1.2s to 3.0±0.3s, respectively. This could be expected as the P metabolites in blood are predominantly
intracellular, and thus, there is no direct contact with the extracellular contrast agent that would influence the relaxation time, as is the case for the water signal. The effect on
transverse relaxation (T ) of water  was ignored in this study as P metabolites have short T  times without contrast, and thus free induction decay signals are typically
acquired in P-MRS . Figure 2 depicts representative high SNR spectra of the blood acquired before and after adding Iopamidol, not showing any visible difference. Similarly,
Figure 3 shows a box-plot diagram of fitted metabolite signals showing no difference. Table 1 summarizes the fit details in all three vials with and without contrast, with no
significant differences found. This supports our finding of no change in the longitudinal relaxation time after adding the contrast agent (Figure 1), suggesting that metabolic
examination using P-MRS after a contrast enhanced CT scan using the Iopamidol contrast agent would not be confounded.
Conclusion:
This study demonstrates that CT contrast agent Iopamidol, while having T  shortening effect on water signal, has no measurable effect on the P-MRS signal. Therefore, we
propose that P-MRS datasets obtained in patients shortly after contrast-enhanced CT are directly quantifiable and comparable to those obtained without prior administration
of CT contrast.
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Figures
Figure 1: Mono-exponential T  fits of water and DPG signals of human blood pre- and post- addition of a clinical dose of CT contrast agent. The iodinated contrast agent
shortens the T  of water substantially while having no observable effect on the relaxation of the DPG signal.
Figure 2: P-MR spectra acquired from whole human blood before (brown) and after (grey) addition of Iopamidol. The magnitudes of 2,3-DPG, PDE, γ-ATP and α-ATP are all
unaffected by the contrast agent.
Figure 3: Iodinated contrast agent Iopamidol has no effect on the P-MR signal of any of the observed metabolites, suggesting that a P-MRS examination is feasible
immediately after a contrast enhanced CT scan.
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Table 1: Metabolite signal measured in each blood vial before and after adding contrast agent. The last column provides the p-values of the paired t-test.
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